No Data
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,247
Trending Stocks Today | TELESIS BIO Shoots up 124.13% Post-Market
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics